ROE

Exodus reports a surge in users and swap volume for January, defying a market downturn while strategically increasing its Solana treasury holdings.

The asset manager starts 2026 with a bang, fueled by massive European inflows, a strategic shift to higher-fee products, and resilient digital asset growth.

A new deal for the rare isotope Actinium-225 could break a major supply bottleneck, accelerating the development of highly targeted cancer treatments.

With its foundational drug a success, Madrigal bets billions on next-gen siRNA tech, aiming to fuse it with Rezdiffra and dominate MASH treatment.

Franklin Templeton and Binance launch a landmark program allowing institutions to use tokenized assets as collateral, bridging traditional and digital finance.

With French state backing, Eutelsat secures €1bn to build its next-gen OneWeb LEO constellation, intensifying the global satellite internet race.

With a 135% revenue surge and a key FDA submission for its kidney transplant drug, Hansa Biopharma is poised for a pivotal year of expansion.

New US tax rules have fundamentally changed the economics of software development: domestic engineers and AI hardware are now fully deductible in year one, while offshore talent costs must be amortized over 15 years. This report details how the resulting "tax wedge" is dismantling the traditional offshoring model and driving a strategic shift toward re-onshoring and automation.

A new report shows the carbon removal market has the tools to fight climate change, but widespread corporate inaction threatens to strand vital projects.

Fresh off a strategic rebrand and a record-breaking year, Potomac Bancshares is courting investors and cementing its role as a Mid-Atlantic banking leader.

With its IPO complete, Cambridge Acquisition Corp. enters a disciplined SPAC market with a clear focus on wellness, hemp, and psychedelic tech targets.

Real estate giant KDC is pivoting to power the AI boom, hiring an industry expert to scale its national data center platform amid explosive demand.

A national report card gives the U.S. a 'B' on rare disease policy, but stark state-by-state disparities leave millions vulnerable to financial ruin.

A spike in layoffs to 14-year highs clashes with extreme investor optimism, raising fears of a major market correction on the horizon for 2026.

Bionano's 2026 virtual event will showcase how Optical Genome Mapping is revolutionizing cancer and genetic disease research and paving a path to clinical use.

IN8bio promotes Kate Rochlin to President, signaling a strategic push to advance its promising gamma-delta T cell pipeline amid a challenging market.

With a promising spinal cord injury drug nearing late-stage trials, NervGen appoints interim leader Dr. Adam Rogers as permanent CEO to guide the breakthrough.

The Middle East healthcare giant posts record profits and a $163M dividend, fueled by aggressive international acquisitions and a major bet on AI technology.

The medical device giant posts 6% Q1 growth but faces major challenges from US reimbursement changes and a China recall, banking on a new acquisition.

Horizon Media's new HorizonOS integrates Intent IQ's identity tech to unlock valuable, hard-to-reach audiences on iOS, CTV, and cookieless browsers.